X
Access Company Profiles

Get business overview, business operations details specific to this market, products and services, latest developments and more...

Business Email

Select Companies

 

Peptide Therapeutics Companies (2024 - 2029)

Companies in the pharmaceutical sector are continuously striving to develop and improve their products. These firms are heavily invested in research and development, working diligently to create innovative solutions for a variety of health conditions. The industry is highly competitive, with each business aiming to deliver the most effective and groundbreaking treatments. These corporations are also focused on ensuring the safety and efficacy of their products, adhering to strict regulatory standards. In summary, these enterprises are at the forefront of medical advancements, contributing significantly to the healthcare sector.

Home Market Analysis Healthcare Research Pharmaceuticals Research Active Pharmaceutical Ingredients Research Synthetic Compounds Research Peptide Therapeutics Market Companies

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Top Companies in Peptide Therapeutics Market

This report lists the top Peptide Therapeutics companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Peptide Therapeutics industry.

  1. Eli Lilly and Company

  2. Amgen

  3. Bristol-Myers Squibb

  4. GlaxoSmithKline

  5. AstraZeneca

*Disclaimer: Top companies sorted in no particular order

Peptide Therapeutics Market Major Players

Peptide Therapeutics Market Concentration

Peptide Therapeutics Market Concentration

Peptide Therapeutics Company List

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions & Market Definition

    2. 1.2 Scope Of The Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Cancer and Metabolic Disorders

      2. 4.2.2 Rising Investments in Research and Development of Novel Drugs

      3. 4.2.3 Technological Advancements

    3. 4.3 Market Restraints

      1. 4.3.1 Instability of Peptides

      2. 4.3.2 High Cost of Developing Drugs and Stringent Regulatory Requirements for Drug Approval

    4. 4.4 Industry Attractiveness - Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD Million)

    1. 5.1 By Marketing Type

      1. 5.1.1 Generic

      2. 5.1.2 Branded

    2. 5.2 By Application

      1. 5.2.1 Gastrointestinal Disorders

      2. 5.2.2 Neurological Disorders

      3. 5.2.3 Metabolic Disorders

      4. 5.2.4 Cancer

      5. 5.2.5 Other Applications

    3. 5.3 By Route of Administration

      1. 5.3.1 Parenteral

      2. 5.3.2 Oral

      3. 5.3.3 Other Routes of Administration

    4. 5.4 By Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Eli Lilly and Company

      2. 6.1.2 Amgen Inc.

      3. 6.1.3 Pfizer Inc.

      4. 6.1.4 Bristol-Myers Squibb Company

      5. 6.1.5 Ever Neuro Pharma GmbH

      6. 6.1.6 Takeda Pharmaceutical Company Limited

      7. 6.1.7 Teva Pharmaceuticals Industries Ltd

      8. 6.1.8 AstraZeneca PLC

      9. 6.1.9 GlaxoSmithKline PLC

      10. 6.1.10 Novo Nordisk AS

      11. 6.1.11 Novartis AG

      12. 6.1.12 Zealand Pharma AG

      13. 6.1.13 SELLAS Life Sciences Group (Galena Biopharmaceuticals)

    2. *List Not Exhaustive

  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS


Specific to Peptide Therapeutics Market
Need More Details On Market Players And Competitors?
Download PDF

Competitive Landscape Report Includes

Company Profiles (includes Global Level Overview, Market Level Overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and Analysis of Recent Developments). Key Strategic Moves, Market Share Analysis, Company Landscape, and List of Companies.

Peptide Therapeutics Market Companies Summary

The peptide therapeutics market has seen substantial growth due to the COVID-19 pandemic, with businesses developing peptide-based vaccines for treatment. The surge in COVID-19 cases initially drove the market growth, as peptide therapeutics were found effective for treating Sars-CoV-2 infection. However, as the pandemic has declined, the market may be negatively impacted. Despite this, the efficacy of peptide therapeutics in treating other chronic diseases is expected to ensure stable growth in the market over the forecast period. The market growth is also driven by the increasing prevalence of cancer and metabolic disorders, rising investments in research and development of novel drugs, and technological advancements in peptide therapeutics. Companies are capitalizing on the increasing number of cancer cases and the significant effect of peptide therapeutics in cancer treatment. Additionally, the high prevalence of metabolic disorders is fueling the demand for peptide therapeutics for treating these disorders, thereby driving the growth of the market. Technological development and the introduction of new peptide therapeutics for treating chronic diseases like cancer are also fueling the growth of the market. However, instability issues of peptide therapeutics, the high cost of developing drugs, and stringent regulatory requirements for drug approval are expected to restrain the market growth.

Explore More

Peptide Therapeutics Companies - Table of Contents

  1. 1. COMPETITIVE LANDSCAPE

    1. 1.1 Company Profiles

      1. 1.1.1 Eli Lilly and Company

      2. 1.1.2 Amgen Inc.

      3. 1.1.3 Pfizer Inc.

      4. 1.1.4 Bristol-Myers Squibb Company

      5. 1.1.5 Ever Neuro Pharma GmbH

      6. 1.1.6 Takeda Pharmaceutical Company Limited

      7. 1.1.7 Teva Pharmaceuticals Industries Ltd

      8. 1.1.8 AstraZeneca PLC

      9. 1.1.9 GlaxoSmithKline PLC

      10. 1.1.10 Novo Nordisk AS

      11. 1.1.11 Novartis AG

      12. 1.1.12 Zealand Pharma AG

      13. 1.1.13 SELLAS Life Sciences Group (Galena Biopharmaceuticals)

    2. *List Not Exhaustive

Peptide Therapeutics Companies FAQs

Eli Lilly and Company, Amgen Inc., Bristol-Myers Squibb Company, GlaxoSmithKline PLC and AstraZeneca PLC are the major companies operating in the Peptide Therapeutics Market.

Peptide Therapeutics Market Report Snapshots

Peptide Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)